BofA upgraded Novartis (NVS) to Buy from Neutral with a price target of CHF 117, up from CHF 111. A long-standing overhang for investors has been the company’s substantial patent cliffs into the end of the decade, with Cosentyx, Kesimpta and Kisqali, but the firm notes that the company already has several launches succeeding – including Pluvicto, Scemblix, and Leqvio – with new launches likely to add in Rhapsido and ianalumab.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVS:
- Novartis AG: Strong Growth Potential Amid Patent Expirations with Robust Pipeline and Strategic Phase III Trials
- Novartis receives FDA approval for Itvisma
- Labcorp appoints Victor Bulto to Board of Directors
- Morning Movers: Walmart gains, Bath & Body Works plummets after Q3 reports
- Novartis sees +5%-6% sales CAGR cc for 2025-2030